Alport syndrome and thin basement membrane nephropathy
Log in to starLast updated Nov 3, 2026
A teenage boy with progressive sensorineural hearing loss and anterior lenticonus on eye exam has microscopic hematuria and proteinuria. His maternal uncle is on dialysis. Mother has lifelong asymptomatic microscopic hematuria, a classic carrier presentation.
XL (COL4A5), AR or AD (COL4A3, COL4A4); the genes encode the α5, α3, and α4 chains of collagen IV. Absent or defective α3/α4/α5 networks in basement membranes cause the disease.
Alport syndrome (AS) and thin basement membrane nephropathy (TBMN) are now understood as a type IV collagen disease spectrum, with TBMN as the mildest end and X-linked AS as the most severe.
| Form | Inheritance | Genes | Severity |
|---|---|---|---|
| X-linked Alport | XLD | COL4A5 | Severe in males (ESRD by 20s-30s); female carriers variable |
| Autosomal recessive Alport | AR | COL4A3, COL4A4 (biallelic) | Severe; both sexes equally |
| Autosomal dominant Alport | AD | COL4A3, COL4A4 (heterozygous, severe variants) | Variable, often progressive |
| Thin basement membrane nephropathy (TBMN) | AD | COL4A3, COL4A4 (heterozygous, milder variants) | Mild: isolated hematuria, generally benign |
The same heterozygous COL4A3/A4 variants can present as either AD Alport or TBMN depending on variant severity, modifiers, and chance; they are increasingly grouped under "autosomal dominant Alport spectrum."
Collagen IV is the major collagen of basement membranes. Its α chains form triple-helical heterotrimers that link into networks. As the glomerulus matures, the α3, α4, and α5 chains replace the α1 and α2 chains of the immature glomerulus as the main collagen IV of the glomerular basement membrane.
A pathogenic variant in one chain of the α3/α4/α5 network can keep all three chains out of the basement membrane. Most missense variants replace a glycine in the Gly-X-Y repeat; the bulkier residue presumably kinks or unfolds the triple helix, and the misfolded helix is degraded faster.
- COL4A5 males: large rearrangements and nonsense or frameshift variants give a 50% chance of kidney failure before age 20 and of deafness by age 10; missense variants give a 50% chance of kidney failure by age 40.
- COL4A5 females: severity may depend on the variant and on skewed X inactivation.
- COL4A3 and COL4A4: the variant type does not predict recessive or dominant disease. Heterozygotes show reduced penetrance, with an absolute risk of kidney failure well below 3%.
- Deletions spanning the 5' ends of COL4A5 and COL4A6, with the COL4A6 breakpoint in its second intron, add diffuse leiomyomatosis; deletions extending beyond that intron do not.
- Type IV collagen defect affecting basement membranes
- Renal: persistent microscopic hematuria, proteinuria, progressive renal failure
- Males with XL form → ESRD typically by 20s-30s
- Females with XL form → variable; ~20% develop ESRD by age 60
- Biallelic AR → severe early disease both sexes
- Hearing: progressive sensorineural hearing loss (~50%-60% of XL males, less in carriers)
- Ocular: anterior lenticonus (pathognomonic), macular flecks, corneal dystrophy
Historically called "benign familial hematuria." Now recognized as the mild end of the COL4A3/A4 spectrum:
- Persistent microscopic hematuria, often present from childhood
- Family history of microscopic hematuria (autosomal dominant pattern)
- No or minimal proteinuria
- Normal hearing, normal eye exam
- Renal function usually preserved, but a subset progress to CKD especially with cofactors (hypertension, obesity, additional kidney insults)
Why it matters: TBMN was historically considered benign, but ~30% of COL4A3/A4 heterozygotes develop CKD by age 60. Today, isolated hematuria with a COL4A3/A4 variant is treated as a kidney disease that warrants surveillance, not a no-touch diagnosis.
- Urinalysis: persistent dysmorphic RBCs, proteinuria
- Audiology baseline and serial
- Eye exam for lenticonus and macular flecks
- Kidney biopsy: electron microscopy shows characteristic GBM thinning, splitting, and lamellation in Alport; uniform thinning in TBMN
- Genetic testing: multigene panel covering COL4A3, COL4A4, COL4A5; preferred over biopsy when available because it discriminates the inheritance pattern and informs family testing
- IgA nephropathy: recurrent gross hematuria with URIs; mesangial IgA on biopsy
- Post-infectious glomerulonephritis: acute nephritic syndrome after strep
- Thin basement membrane nephropathy (within-spectrum): addressed above
- Fabry disease: GLA, X-linked, lysosomal; renal disease + skin angiokeratomas + cardiac
- Polycystic kidney disease: cysts on ultrasound, no hematuria pattern
- ACE inhibitors / ARBs: first-line, slow progression of proteinuria; start early
- SGLT2 inhibitors: emerging evidence for slowing progression
- Avoid nephrotoxins (NSAIDs, aminoglycosides where possible)
- Audiology + eye surveillance in Alport
- Transplantation for ESRD; ~3% develop anti-GBM disease against the new healthy kidney's α5(IV) collagen, so counsel before transplant
- Carrier counseling for relatives; even mild COL4 variants warrant kidney follow-up
Alport affects all the "ports": Eyes, ears, kidneys.
ALport = Anterior Lenticonus, the pathognomonic eye finding.
Alfourt involves type four collagen.
TBMN = "Thin BM, Mild Nephritis": the mild end of the COL4 spectrum. Isolated hematuria + family history without hearing or eye findings, but worth surveillance because ~30% progress.